Positive initiatives in therapeutic areas
At Consilient Health, innovative solutions for patient health are our focus.
We offer a wide variety of prescription medicines, including a licensed vitamin D range and products in women’s health, urology, child mental health and for smoking. We partner with the NHS to drive the reliable provision of high-quality medicines and cost-savings for the NHS, complemented by comprehensive support programs for both medical professionals and patients.
For access to the summary of product characteristics, patient information leaflets, and available risk minimisation measures, please view the product section below.
Women’s Health
Consilient Health continues to invest in therapies for our women’s health portfolio. We always look to build in value for both healthcare professionals and patients.
We have a product for women with the menopause and we continue to provide educational resources for both patients and healthcare professionals in this important therapy area.
Endocrinology Portfolio Information
Since launching our first endocrinology product in 2014, Consilient Health has successfully launched products in this therapeutic area including medicines to optimise bone health. These are managed by our UK and European business units.
Providing innovative solutions for prescribers and patients is a key element of our offering. Consilient Health is a valued strategic partner with plans to continue its expansion in this area over the coming years.
Urology
Consilient Health is proud to have brought to market a specialist urology product used to treat a rare and potentially debilitating urological condition. The disease is poorly understood and treatment options are limited.
This is in keeping with our desire to bring to the market medicines that have a clear differentiation and where there is an unmet clinical need.
Child Mental Health
Consilient Health is proud to invest in bringing products to the market for child mental health.
The additions to our portfolio underscore our commitment to diversifying treatment options, seeking to improve patient choice and accessibility of treatment, and enhance the patient experience.
Smoking
Smoking is the UK’s biggest preventable killer – causing around 1 in 4 cancer deaths and leading to 64,000 deaths per year in England. It is also one of the biggest drivers of health inequalities across the country, and tackling this is a priority to improve public health.
Consilient Health is proud to invest in this area of significant unmet need and remains dedicated to bringing forward treatments that can make a real difference in people’s lives.
Products